Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Vaccine
Cure© Hosts Power of X Summit to Drive Investment and Solutions in Untapped Trillion-Dollar Market Addressing Health of Women
Event's Impact Challenge to Award One Early-Stage Company Up to $100K for Innovative Women's Health Solutions NEW YORK, March 6,...
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J., March 6,...
Dyadic to Attend Multiple Industry Events in March
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI),...
Medical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight Partners
NEW YORK, March 4, 2025 /PRNewswire/ -- According to a comprehensive report from The Insight Partners, "Medical Refrigerators Market Size and...
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader...
GenBio AI Expands Global Leadership with Ziv Bar-Joseph as Co-Founder and Chief Scientific Officer
PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited...
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product...
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance
Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue...
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as...
Novavax to Participate in Upcoming March Investor Conferences
GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in...
Anivive Sponsors 69th Annual Coccidioidomycosis Study Group Meeting
Hosted by Arizona State University and Mayo ClinicAnivive provides $50,000 in travel awardsLeading global experts pioneering novel fungal vaccines, therapeutics...
A Decade of Black Excellence: Finalists of Anticipated Top Blacks in Healthcare (TBH) Awards Announced
CHICAGO, Feb. 27, 2025 /PRNewswire/ -- BlackDoctor.org (BDO), a nationally recognized leader in Black health, announces finalists of its 10th...
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader...
Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities
HOUSTON, Feb. 26, 2025 /PRNewswire/ -- Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical...
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to...
Alveo Technologies and Royal GD Form Long-Term Partnership to Expand Joint Offerings for Rapid, Molecular Animal Diagnostics at Point-of-Need
Their first co-developed product, Alveo Sense™ Poultry Avian Influenza was introduced in the EU in late 2024 and is now...
Groundbreaking Health Podcast “Docology” Launching March 18th
Global Health Leader Howard Zucker Teams With HANG Media to Invite the Audience Onto The Show NEW YORK, Feb....
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...